

Years 2021

Date of last update	Regimen Name on NCCP website	Tumour Group	Regimen Number
May	Bortezomib Maintenance Therapy- 14 day	Myeloma	435
	CHOEP Therapy- 21 days	Lymphoma	396
	DOXOrubicin and Cyclophosphamide (AC 60/600) Therapy-21 day	Breast	252
	epiRUBicin 90 + Cyclophosphamide (EC90) Therapy - 21 day	Breast	262
	Talazoparib Therapy	Breast	605
Jun	5-Fluorouracil 225mg/m2/day and Radiotherapy (RT)- Continuous infusion 7 day	Gastrointestinal	421
	CARBOplatin (AUC 2) Weekly and PACLitaxel (50mg/m2) Weekly with Radiotherapy (RT) -5 weeks	Gastrointestinal	422
	CISplatin (50mg/m2) Etoposide (100mg/m2) and Thoracic Radiotherapy (TRT) -28 day	Lung	456
	CISplatin (75mg/m2) + Etoposide (100mg/m2) +Thoracic Radiotherapy (TRT) - 21 day	Lung	279
	CISplatin (75mg/m2) + Etoposide Therapy-21 day	Lung	280
	Dacomitinib Monotherapy	Lung	565
	Encorafenib and Binimetinib Therapy	Skin/Melanoma	563
	epiRUBicin, CISplatin and 5-FU (ECF) Therapy	Gastrointestinal	240
	epiRUBicin, Oxaliplatin and Capecitabine (EOX) Therapy	Gastrointestinal	239
	Gemcitabine (1250mg/m2) and CISplatin (75mg/m2) Therapy- 21 day	Lung	281
	Gemcitabine (600mg/m2) and RT therapy	Gastrointestinal	559

Jun	Modified Roswell Park (Fluorouracil 500mg/m ² and Folinic Acid 50mg weekly x 6) Regimen	Gastrointestinal	427
	Pembrolizumab, PEMEtrexed and CISplatin Therapy	Lung	569
	PEMEtrexed and CISplatin Therapy	Lung	317
	Ponatinib Therapy	Leukaemia/BMT	302
	QUASAR (Modified) Fluorouracil(370mg/m ²) and Folinic Acid (50mg) Weekly	Gastrointestinal	428
	Vinorelbine and CISplatin Therapy-21 days	Lung	339
	Vinorelbine and CISplatin Therapy-28 days	Lung	343
	Bevacizumab 7.5mg/kg, CARBOplatin (AUC5) and PACLitaxel 175mg/m ² Therapy	Gynaecology	620
	5-Fluorouracil and Folinic Acid Therapy-14 day	Gastrointestinal	660
	Jul	(R**)- miniCHOP Therapy – 21 days	Lymphoma
CARBOplatin (AUC4-6) Monotherapy-21 days		Breast	261
		Gynaecology	261
CARBOplatin (AUC4-6) Monotherapy-28 days		Breast	251
		Gynaecology	251
Enzalutamide Monotherapy		Genitourinary	233
epiRUBicin, Oxaliplatin and 5-FU (EOF) Therapy -21 day		Gastrointestinal	429
FOLFOXIRI Therapy		Gastrointestinal	555
Oral Vinorelbine Monotherapy-7days		Breast	259
		Lung	259
pertuzumab and trastuzumab and chemotherapy -21 day cycles		Breast	350
Trastuzumab (IV) Monotherapy 21 days		Breast	200
Trastuzumab Emtansine (Kadcyla®) - 21 days		Breast	206
Niraparib Monotherapy	Gynaecology	571	

Jul	riTUXimab S/C, Cyclophosphamide, DOXOrubicin, VinCRISTine and Prednisolone (R-CHOP) Therapy– 21 Days	Lymphoma	667
Aug	Apalutamide therapy	Genitourinary	574
	Procarbazine, Lomustine and VinCRISTine (PCV) Therapy – 56 days	Neuro-oncology	658
	CISplatin (50mg/m2) Chemoradiation followed by CARBOplatin (AUC 5) and PACLitaxel (175mg/m2) – Endometrial Cancer	Gynaecology	676
	Busulfan/Cyclophosphamide/A TG Grafalon® – MAC –Mismatched Unrelated Donor	Transplant	663
	Busulfan/Cyclophosphamide/A TG Grafalon® – MAC –Mismatched Sibling Donor	Transplant	662
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Unrelated Donor	Transplant	629
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–Mismatched Sibling Donor	Transplant	630
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–MUD	Transplant	631
	Cyclophosphamide/Total Body Irradiation (TBI)–MAC–SIB	Transplant	637
	Fludarabine/Busulfan/ATG Grafalon® – RIC – MUD	Transplant	635
	Fludarabine/Busulfan/ATG Grafalon® – RIC –SIB	Transplant	636
	Fludarabine/Melphalan/Alemt uzumab-RIC-MUD	Transplant	625
	Fludarabine/Melphalan/Alemt uzumab-RIC-SIB	Transplant	611

Aug	Carmustine/Etoposide/Cytarabine/Melphalan/Alemtuzumab RIC-SIB/MUD	Transplant	638
	Busulfan/Cyclophosphamide MAC-MUD	Transplant	639
	Busulfan/Cyclophosphamide MAC-SIB	Transplant	641
Sep	ABVD Therapy	Lymphoma	290
	CISplatin (100mg/m ²) with Radiotherapy (RT)	Head & Neck	387
	Daratumumab (IV), bortezomib and dexamethasone therapy	Myeloma	560
	Daratumumab (SC 1800mg), Bortezomib and Dexamethasone Therapy	Myeloma	609
	Daratumumab SC Monotherapy	Myeloma	604
	DOCEtaxel /Cyclophosphamide (TC) Therapy-21 day	Breast	250
	DOCEtaxel 75mg/m ² - Prednisolone combination therapy	Genitourinary	546
	DOCEtaxel Monotherapy 100mg/m ² – 21 day cycle	Breast	202
	DOCEtaxel Monotherapy 75mg/m ² – 21 day cycle	Lung	203
	DOCEtaxel Monotherapy 50mg/m ² Monotherapy-14 day	Genitourinary	313
	DOCEtaxel, CARBOplatin and Trastuzumab (TCH) - 21 days	Breast	258
	DOCEtaxel, CISplatin, 5-Fluorouracil and Radiotherapy	Head & Neck	324
	DOCEtaxel,CISplatin and 5-Fluorouracil Chemoradiation (Induction) Therapy	Head & Neck	323
	DOXOrubicin 50mg/m ² /DOCEtaxel 75mg/m ² (AT 50/75) Therapy - 21 day cycle	Breast	423
	FLAG:Ida 8mg/m ² Therapy	Leukaemia/BMT	362
	FLOT Therapy-14 day	Gastrointestinal	344
	FOLFIRI (14 days)+ Cetuximab (7 days) Therapy	Gastrointestinal	328

Sep	Gemcitabine and DOCEtaxel Therapy - 21 day	Sarcoma	501
	High Dose Melphalan Conditioning Therapy for Autologous Stem Cell Transplant	Lymphoma	454
		Myeloma	454
	High dose Methotrexate, high dose cytarabine, riTUXimab and thiotepa (MATRix) therapy	Lymphoma	508
	Imatinib Therapy-GIST	Sarcoma	335
	Neoadjuvant DOCEtaxel, CISplatin, 5-Fluorouracil and Chemoradiation and Surgery	Head & Neck	315
	Nindetanib Therapy	Lung	372
	Pazopanib Therapy	Genitourinary	445
		Sarcoma	445
	Pembrolizumab 200mg Monotherapy	Genitourinary	455
		Lung	455
		Lymphoma	455
		Skin/Melanoma	455
	Pertuzumab + Trastuzumab + DOCEtaxel	Breast	204
	Tivozanib Therapy	Genitourinary	564
	Trastuzumab SC 21 days-Early Breast Cancer	Breast	285
	Trastuzumab Subcutaneous 21 days- Metastatic Breast Carcinoma	Breast	272
	FLAG Therapy	Leukaemia	363
	Dose Adjusted R (S/C)-EPOCH Therapy	Lymphoma	672
Oct	(**riTUXimab) Cyclophosphamide, DOXOrubicin, vinCRISTine and Prednisolone (*R)-CHOP Therapy– 14 days	Lymphoma	409
		Lymphoma	307
	Atezolizumab 1200mg Monotherapy	Genitourinary	544
		Lung	544
	Atezolizumab 1680mg Monotherapy – 28 Day	Genitourinary	593
		Lung	593

Oct	Osimertinib Monotherapy	Lung	353
	Cyclophosphamide, DOXOrubicin, vinCRISTine and prednisoLONE (CHOP) Therapy– 21 days	Lymphoma	307.1
	Acalabrutinib Monotherapy	Leukaemia	656
	Midostaurin (DAUNOrubicin and Cytarabine) Induction Therapy	Leukaemia	682